Research summary
The study characterizes a Fas epitope involved in agonist antibody activity and CAR-T bystander effects in ovarian cancer models.
Study context
The regulatory Fas epitope
Which Fas receptor features determine whether an antibody triggers death signaling in the studied ovarian cancer setting?
How it was studied
The paper combines antibody epitope characterization, Fas receptor perturbations, cell-death assays and ovarian cancer models, alongside CAR-T bystander experiments. Its mechanistic claims should be read with the exact receptor and cell conditions reported in the article.
Selected findings
- The study identifies a regulatory Fas epitope critical for the tested agonist antibodies.
- Experiments connect epitope access and receptor glycosylation context to differential antibody activity.
Preclinical receptor and tumor-model experiments. The results do not establish safety or efficacy of a Fas therapy in patients, nor do they imply that every CAR-T bystander effect is Fas-mediated.
Read the full project analysis → · View publication figures →
Authors
Cite this work
Tanmoy Mondal, Himanshu Gaur, Brice E N Wamba, Abby Grace Michalak, Camryn Stout, Matthew R Watson, Sophia L Aleixo, Arjun Singh, Salvatore Condello, Roland Faller, Gary Scott Leiserowitz, Sanchita Bhatnagar, Jogender Tushir-Singh (2023). Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer. Cell death and differentiation, 2408-2431. https://doi.org/10.1038/s41418-023-01229-7